• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $SCNX

    Scienture Holdings Inc.

    Subscribe to $SCNX
    $SCNX
    Other Pharmaceuticals
    Health Care

    IPO Year:

    Exchange: NASDAQ

    Recent Analyst Ratings for Scienture Holdings Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Scienture Holdings Inc. Leadership Updates

    Live Leadership Updates

    See more
    • SCIENTURE Announces Executive Leadership Transition

      TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

      5/22/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care

    Scienture Holdings Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Scienture Holdings Inc.

      10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

      5/12/25 5:30:35 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B3 filed by Scienture Holdings Inc.

      424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

      4/24/25 4:05:28 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Scienture Holdings Inc.

      EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

      4/14/25 12:15:17 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B3 filed by Scienture Holdings Inc.

      424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

      4/11/25 4:50:55 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form S-1 filed by Scienture Holdings Inc.

      S-1 - Scienture Holdings, Inc. (0001382574) (Filer)

      4/4/25 5:11:54 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-K filed by Scienture Holdings Inc.

      10-K - Scienture Holdings, Inc. (0001382574) (Filer)

      3/25/25 8:28:20 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Scienture Holdings, Inc. (0001382574) (Filer)

      3/21/25 4:20:34 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Scienture Holdings, Inc. (0001382574) (Filer)

      3/13/25 4:27:27 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Scienture Holdings, Inc. (0001382574) (Filer)

      3/10/25 5:27:22 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B3 filed by Scienture Holdings Inc.

      424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

      2/24/25 4:05:31 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care

    Scienture Holdings Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SCIENTURE Announces Executive Leadership Transition

      TAMPA, FL, May 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced that Suren Ajjarapu, who has served as Chief Executive Officer (CEO) and Chairman of the Board of Directors (BOD), has stepped down from his roles with the Company, with those positions being assumed by the existing, experienced management team of Dr. Shankar Hariharan and Dr. Narasimhan Mani. Shankar Hariharan, P

      5/22/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

      TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that the U.S. Food and Drug Administration (FDA) has listed U.S. Patent Nos. 11890273 (the ‘273 patent) and 12156869 (the '869 patent), each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) for Arbli™, (losartan potassium) Ora

      5/19/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

      TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC

      4/22/25 8:04:59 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

      TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum Health, Inc., and Softell, Inc. to Tollo Health, Inc. for a total consideration of $5 million. The divestitures are part of a broader strategic realignment at the Company designed to sharpen operatio

      4/8/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings, Inc. Issues Annual Letter to Shareholders

      TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through

      4/3/25 8:26:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

      TAMPA, FL, March 25, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce Michele Rath as Senior Vice President and Chief Commercial Officer (CCO) of Scienture, LLC, a wholly owned subsidiary of the Company, leading and managing Scienture, LLC's commercial operations. Under Ms. Rath's leadership, Scienture, LLC has formalized a strategic relationship with Syneos Health Commercia

      3/25/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

      TAMPA, FL, March 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, today announced it has completed a draw on its Equity Line of Credit (ELOC) to support the commercial launch of Arbli™ (losartan potassium) Oral Suspension, while simultaneously announcing a temporary suspension of further ELOC draws for the next 30 trading days or until the company's stock reaches $10 per share, whichever occurs first. The st

      3/19/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

      TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- – SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the U.S. Food and Drug Administration (FDA) has approved SCN-102, one of the products being developed by Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc., with the brand name ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL. ArbliTM is meant for the treatment of hypertension in patients great

      3/18/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

      TAMPA, FL, March 06, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce that its wholly owned subsidiary, Scienture, LLC ("Scienture"), has entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly owned subsidiary of Kindeva Drug Delivery L.P. ("Kindeva")), for the exclusive U.S. rights to commercially launch REZENOPY® (naloxone HCl) Nasal Spray 10mg, an opioid antagonist th

      3/6/25 7:40:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

      TAMPA, FL, Jan. 21, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX), a Specialty Pharma company with a novel pipeline of brand products, is pleased to announce the participation of Narasimhan Mani, Ph.D., MBA (President of Scienture, LLC) as an invited speaker and panelist at the 8th Annual Conference of The Society for the Study of Xenobiotics (SSX) India, one of the premiere conferences organized in India specifically in the area of drug discovery and development. The conference will take place January 23-25, 2025, at BITS Pilani, Hyderabad Campus in Hyderabad, India. Dr. Mani will deliver a presentation on the specialty pharmaceutical industry with a specific focus on t

      1/21/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care